Introduction
Ewing'sSarcoma/PNET of the female genital tract is very unusual, but has been reported to involve the ovary, uterine corpus, uterine cervix, and vulva. To our knowledge, only 10-12 cases of primary vaginal Ewing'sSarcoma/PNET have been previously reported in the literature and none of them had any evidence of metastasis when reported. Here, we present a rare case of primary vaginal Ewing's Sarcoma/PNET with liver, breast and lung metastasis.
Case Report
We present a case of a 45 year old woman, gravida 2, para 2, with who presented with the complaints of whitish, foul smelling vaginal discharge and swelling at vulva since 2 months and itching at the local site since 1 month. Per vaginal & per speculum examination of vagina showed 6X6 cm submucosal growth over left sided vulva, disease CECT Pelvis showed a 57X47X120 mm lesion with internal necrotic area involving vagina more on left side and extending upto labial fold, both is chiorectal fossa and infiltrating the proximal part of the leftobturator internus, loss of fat plane with rectum and anal canal; 40X38mm fibroid involving fundus of uterus;bilateral adnexa were normal with no ascites or lymphadenopathy. Bone scan was normal. 
Result
Our patient was regular in treatment.
Discussion
Ewing's sarcoma has a potential for haematogenous metastasis and the most common sites of metastasis include lungs, bones and bone marrow. About 25% of patients have metastatic disease at presentation, patients with isolated lung metastasis have better prognosis than those with extrapulmonary disease. The chemotherapy regimen and initial treatment for patients with metastatic disease is the same as that for localized disease. At the time of local therapy, all sites of the disease must be re-evaluated. If tumor shows progression or there is persistence of widespread disease, there is little hope for cure and hence, such patients should be treated with palliative intent. For patients responding well, at this stage, local therapy in the form of surgery and/or radiation is recommended to the primary site as well as all metastatic sites. Management of vaginal Ewing's sarcoma is controversial, due to rarity of its presentation.
Conclusion
Our case report describes a rare site of primary vaginal Ewing's sarcoma/PNET in the 45 year old patient. It reinforces the value of IHC, emphasizing the utility of immunohistochemical staining in establishing the diagnosis of tumours at unusual sites. Further the case also highlights the utility of induction chemotherapy followed by radiation treatment and subsequent palliative chemotherapy as a treatment modality.
